The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting.
Rashmi Krishna Murthy
Honoraria - Amgen
Ankur Varma
No relevant relationships to disclose
Priyankana Mishra
No relevant relationships to disclose
Kenneth R. Hess
No relevant relationships to disclose
Elliana J. Young
No relevant relationships to disclose
James L. Murray
No relevant relationships to disclose
Kimberly Higginbotham Koenig
No relevant relationships to disclose
Marjorie C. Green
No relevant relationships to disclose
Stacy L. Moulder
Honoraria - AstraZeneca (I); Roche (I); Sanofi (I); Wyeth (I)
Amal Melhem-Bertrandt
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Daniel J. Booser
No relevant relationships to disclose
Vicente Valero
No relevant relationships to disclose
Gabriel N. Hortobagyi
Consultant or Advisory Role - Genentech
Francisco J. Esteva
Consultant or Advisory Role - Genentech